Malignancy Clinical Trials in Chicago, Illinois
9 recruitingChicago, Illinois
Showing 1–9 of 9 trials
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Malignancy
Alliance for Clinical Trials in Oncology240 enrolled626 locationsNCT04242095
Recruiting
Not Applicable
Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials
MalignancyCancerMalignant Neoplasm
University of Chicago180 enrolled1 locationNCT05886764
Recruiting
Phase 1
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Not Applicable
Mosaic Trial for Stem Cell Transplant Recipients
Multiple MyelomaLymphomaLeukemia+4 more
Northwestern University356 enrolled3 locationsNCT06960993
Recruiting
Phase 3
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Solid TumorHematologic MalignancyAdvanced Malignancies
Novartis Pharmaceuticals50 enrolled15 locationsNCT06401356
Recruiting
Phase 1
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Hodgkin LymphomaAMLMDS+8 more
Therapeutic Advances in Childhood Leukemia Consortium54 enrolled31 locationsNCT05476770